Table 5.

Phase II and phase III clinical vaccination trials of MenACWY-TT conjugate vaccine in adolescents and adults

Phase	Author	Year	Age group	Country	Registry number at Clinicaltrials.gov
II	Dbaibo et al94	2012	11–34 years	Lebanon	NCT00661557
II	Ostergaard et al99	2013	15–19 years	Denmark	NCT00390143
II	Baxter et al100	2011	10–25 years	USA	NCT00454909
II	Ostergaard et al96	2009	15–19 years 18–25 years	Belgium Denmark	NCT00126945 NCT00196950
II	Borja-Tabora et al98	2013	11–55 years	Philippines Saudi Arabia	NCT00356369
III	Ostergaard et al103	2012	11–17 years	Sweden Denmark	NCT00465816
III	Bermal et al97	2011	11–17 years	Philippines India Taiwan	NCT00464815
III	Dbaibo et al85	2012	18–55 years	Lebanon Philippines	NCT00453986
III	Aplasca-De Los Reyes et al104	2012	18–55 years	Lebanon Philippines	NCT00453986
III	Dbaibo et al46	2013	56–103 years	Lebanon	NCT01235975

Abbreviation: MenACWY-TT, serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine.